The use of urine protein markers in the diagnosis of hereditary angioedema

The identification of specific protein markers by mass spectrometry of urine samples was solved, and the diagnosis of hereditary angioedema was achieved, high sensitivity and specific diagnosis was achieved, the misdiagnosis rate was reduced, and important clinical management basis was provided.

CN114166924BActive Publication Date: 2024-11-22PEKING UNION MEDICAL COLLEGE HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202111464723.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2021-12-03
Publication Date
2024-11-22
Estimated Expiration
2041-12-03

AI Technical Summary

Technical Problem

The prior art is difficult to effectively diagnose hereditary angioedema, resulting in a high misdiagnosis rate and affecting the timely treatment of patients.

Method used

Urine samples were analyzed by mass spectrometry, and specific protein markers were identified and quantitatively detected, such as plasma protease C1 inhibitors, contractile protein alpha chains, etc., which were used to diagnose hereditary angioedema.

Benefits of technology

It improves the diagnostic sensitivity and specificity of hereditary angioedema, can accurately identify patients' risk of disease, reduce the rate of misdiagnosis, and provide an important basis for early diagnosis and management.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0003390871600000091
    Figure BDA0003390871600000091
  • Figure BDA0003390871600000101
    Figure BDA0003390871600000101
  • Figure HDA0003390871610000011
    Figure HDA0003390871610000011
Patent Text Reader

Abstract

The present disclosure relates to the use of urine protein markers in diagnosing hereditary angioedema. Specifically, the present disclosure relates to the use of an identification reagent in preparing a device for diagnosing hereditary angioedema in a subject, wherein the identification reagent specifically identifies one or more of the proteins selected from Table 1. On the other hand, the present disclosure relates to a kit or chip for diagnosing hereditary angioedema, which comprises the identification reagent.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present disclosure relates to clinical medicine, and in particular to urine protein markers associated with human hereditary angioedema. In particular, the present disclosure relates to urine protein markers for diagnosing human hereditary angioedema obtained by using urine samples of hereditary angioedema patients and mass spectrometry proteomics technology, and uses thereof. Background Art

[0002] Disease markers are measurable changes associated with pathophysiological processes and can be used for disease diagnosis, disease course monitoring, efficacy evaluation, etc. Urine is an ideal source of clinical samples for disease markers and can be obtained in large quantities non-invasively. In addition, urine lacks the regulation of homeostatic mechanisms and can enrich various changes excreted by the human body. These changes are potential sources of markers (see Wu J & Gao Y. Physiological conditions can be reflected in human urine proteome and metabolome. Expert Review of Proteomics, 2015; 12(6): 623-636).

[0003] Urinary proteomics aims to establish a non-invasive "liquid biopsy" diagnostic method, which can partially replace tissue biopsy by detecting specific disease markers in urine. It has become an important research direction and has great prospects for clinical transformation and application. DIA (Data independent acquisition) is a new data-independent proteomics quantitative technology. It divides the entire full scan range of the mass spectrometer into several windows to obtain all fragment information of all ions in the sample without difference or omission. Because DIA technology can obtain information on all peptides in clinical samples without discrimination without causing the loss of low-abundance proteins, it is particularly suitable for robust and accurate quantification of proteins under different laboratory conditions (see Navarro P et al. A multicenter study benchmarks software tools for label-free proteome quantification. Nature Biotechnology, 2016; 34(11): 1130-1136). PRM (Parallel reaction monitoring) is a targeted proteomics technology based on the ion monitoring technology of Orbitrap high-resolution mass spectrometry, which can selectively detect the target protein and target peptide to achieve targeted quantification.

[0004] Hereditary angioedema (HAE) is a rare, potentially life-threatening disease characterized by recurrent episodes of subcutaneous and submucosal swelling. HAE is a rare disease with an incidence of 1 in 50,000 people and is often not easily detected. Skin and abdominal attacks are the most common features of HAE, which can easily be misdiagnosed as edema or acute abdomen, causing patients to receive ineffective treatment or unnecessary surgery. In addition, more than 50% of HAE patients will develop laryngeal edema, which can lead to suffocation and death if they are not rescued in time. Therefore, the discovery of early diagnostic markers is crucial to the clinical management of HAE. Summary of the invention

[0005] In view of the above-mentioned needs in the art, according to some embodiments of the present disclosure, there is provided use of an identification reagent selected from any one of the following proteins in the preparation of a diagnostic device for hereditary angioedema:

[0006] Plasma proteinase C1 inhibitor, hexokinases, phenazine biosynthesis domain protein, contractile protein alpha chain, profibrillin 1, cathepsin H precursor, IST1 homologue, malate dehydrogenase, Cochlin, disintegrating and metalloproteinase domain-containing protein 10, basement membrane-specific heparan sulfate proteoglycan core protein, kininogen 1 protein, v-clusters domain-containing inhibitor of T-cell activation 1, epidermal growth factor precursor, junctional adhesion molecule A, N-acetylated alpha-synaptide dipeptidase 2, transmembrane glycoprotein NMB , procollagen c endopeptidase enhancer 2, urokinase plasminogen activator surface receptor, thrombospondin integrin metallopeptidase 1, cathepsin Z, cathepsin L1, endothelial cell selective adhesion molecule, kallikrein 1, complement component C9, complement component C1, calcium binding protein, complement component C7, aquaporin 2, follicle-stimulating hormone beta subunit, protocadherin alpha-C2, vascular endothelial growth factor receptor 2, calcium adhesion-related family member 5, immunoglobulin heavy chain constant region gamma 4, and aspartic proteinase A.

[0007] In a specific embodiment, an increased expression level of a protein selected from the following, compared to the protein level in a control, indicates that the subject suffers from hereditary angioedema or has an increased risk of suffering from hereditary angioedema: contractile protein alpha chain, profibrillin 1, cathepsin H precursor, IST1 homolog, Cochlin, protein 10 containing disintegrating and metalloproteinase domains, basement membrane-specific heparan sulfate proteoglycan core protein, junctional adhesion molecule A, N-acetylated alpha-synaptide dipeptidase 2, transmembrane glycoprotein NMB, procollagen c endopeptidase enhancer 2, urokinase plasminogen activator surface receptor, thrombospondin integrin metallopeptidase 1, cathepsin Z, cathepsin L1, endothelial cell selective adhesion molecule, complement component C9, complement component C1, complement component C7, aquaporin 2, follicle-stimulating hormone beta subunit, protocadherin alpha-C2, vascular endothelial growth factor receptor 2, calcium adhesion-related family member 5, or a combination thereof.

[0008] In a specific embodiment, compared with the protein level in the control, a decrease in the expression level of a protein selected from the following indicates that the subject suffers from hereditary angioedema or has an increased risk of suffering from hereditary angioedema: plasma proteinase C1 inhibitor, hexokinases, phenazine biosynthesis domain protein, malate dehydrogenase, kininogen 1, immunoglobulin heavy chain constant region γ4, V-domain containing T-cell activation inhibitor 1, epidermal growth factor precursor, kallikrein 1, aspartic proteinase A, calcium binding protein or a combination thereof. Otherwise, the risk is reduced.

[0009] In embodiments involving the diagnosis of hereditary angioedema, a control refers to an individual who does not suffer from hereditary angioedema. A control is not necessarily a clinically healthy individual, but is preferably a healthy individual.

[0010] The term "identification reagent" used in this application refers to a reagent capable of quantitatively and / or qualitatively detecting a target protein. Specifically, but not limiting, the identification reagent of the present invention can specifically identify the presence or absence of a target protein in a test sample; or can detect the level of a target protein in a test sample.

[0011] In one embodiment of the present application, the identification reagent is used to identify proteins in urine samples, including but not limited to, for quantitative and / or qualitative detection of proteins in urine samples.

[0012] In one embodiment of the present application, the identification reagent is capable of identifying an increase or decrease in the content of protein in the urine sample of the subject compared to a healthy control group or a non-hereditary angioedema control group, preferably, the increase or decrease is greater than or equal to 1.5 times. The identification reagent of the present application is capable of identifying, or binding to, or searching for, or monitoring, or targeting such a tag peptide (such as a peptide contained in a protein listed in Table 1). In some embodiments, the identification reagent suitable for the present disclosure is a mass spectrometry identification reagent, an antibody, or an antigen-binding fragment thereof.

[0013] In a specific embodiment, the antibody is a monoclonal antibody. The present disclosure has no limitation on the species origin of the monoclonal antibody, and any antibody capable of binding to the above-mentioned protein can be used.

[0014] In a specific embodiment, antigen binding fragments include, but are not limited to: Fab, Fab', (Fab') 2 , Fv, ScFv, bispecific antibody, trispecific antibody, tetraspecific antibody, bi-scFv, mimi antibody. Any antibody fragment that retains antigen binding activity is suitable for the present disclosure.

[0015] In one embodiment, when a mass spectrometry identification reagent is used, the identification reagent is understood broadly and cannot be interpreted only as a chemical or biological reagent that exists in an entity. The term also includes mass spectrometry identification parameters. As an example, the entire full scan range of the mass spectrometer is divided into several windows, and all ions in each window are selected, fragmented, and detected at high speed and cycle, so as to obtain all fragment information of all ions in the sample without omission and difference. This acquisition method is like carpet bombing, hitting all targets without omission; the mass-to-charge ratio information of the fragments is compared in the database to identify the protein identity and quantification. It should be understood that although a specific identification method is used in the specific example, the realization of the technical effect of the present application does not depend on a specific identification method (such as mass spectrometry operation steps, mass spectrometer model, parameters set in the mass spectrometry method, specific peptide sequences identified in mass spectrometry identification, chromatographic column model; antibody supplier, specific epitope targeted by the antibody, antibody typing, immunological operation steps and parameters), because the core of the technical solution of the present application is to find the relationship between the amount of the aforementioned protein in urine and the disease, so any means that can determine the protein content are available.

[0016] Tag peptide (also called specific peptide in this article) refers to a peptide segment that can represent a certain protein, and is characterized by existing and specifically only existing in a certain protein amino acid sequence.

[0017] It should be understood that although the specific examples identify and quantify proteins based on a specific sequence, this does not mean that peptide fragments at other positions in the proteins listed in Table 1 cannot be used, as long as such fragments can distinguish different proteins from each other, they are applicable to this application. Under the guidance of this application, technicians can determine the position or length of the fragment according to conventional techniques combined with the operational requirements of the identification method used.

[0018] In specific embodiments, the expression level is protein level.

[0019] In specific embodiments, the expression level is the level of expression of the protein in a urine sample of a subject.

[0020] In specific embodiments, the subject is a human.

[0021] In the technical solution of the present disclosure, the patient is a patient with hereditary angioedema.

[0022] In specific embodiments, protein markers according to the present disclosure can be used to diagnose hereditary angioedema.

[0023] According to other embodiments, a kit or chip for diagnosing hereditary hematoma is also provided, which comprises an identification reagent selected from the following proteins, or is composed of an identification reagent selected from the following proteins: plasma proteinase C1 inhibitor, hexokinases, phenazine biosynthesis domain protein, contractile protein α chain, profibrillin 1, cathepsin H precursor, IST1 homolog, malate dehydrogenase, Cochlin, protein 10 containing disintegrating and metalloproteinase domains, basement membrane-specific heparin sulfate proteoglycan core protein, kininogen 1, T cell activation inhibitor 1 containing V-clusters, epidermal growth factor precursor , junctional adhesion molecule A, N-acetylated α-synaptide dipeptidase 2, transmembrane glycoprotein NMB, procollagen c endopeptidase enhancer 2, urokinase plasminogen activator surface receptor, thrombospondin integrin metallopeptidase 1, cathepsin Z, cathepsin L1, endothelial cell selective adhesion molecule, kallikrein 1, complement component C9, complement component C1, calcium binding protein, complement component C7, aquaporin 2, follicle-stimulating hormone beta subunit, protocadherin α-C2, vascular endothelial growth factor receptor 2, calcium adhesion-related family member 5, immunoglobulin heavy chain constant region γ4, aspartic proteinase A or a combination thereof.

[0024] In some embodiments, the kit comprises an identification reagent for the above-mentioned protein.

[0025] In other embodiments, the identification reagents of the above proteins are immobilized on the chip.

[0026] In some embodiments, the identification reagent is an antibody or an antigen-binding fragment thereof.

[0027] According to some embodiments, there is provided a method for diagnosing whether a subject has hereditary angioedema, comprising the steps of:

[0028] 1) Obtain urine samples from subjects or controls,

[0029] 2) optionally, isolating protein from the urine sample,

[0030] 3) determining the expression level of a protein selected from the following in the urine sample of the subject:

[0031] Plasma proteinase C1 inhibitor, hexokinases, phenazine biosynthesis domain protein, contractile protein α chain, profibrillin 1, cathepsin H precursor, IST1 homologue, malate dehydrogenase, Cochlin, disintegrating and metalloproteinase domain-containing protein 10, basement membrane-specific heparan sulfate proteoglycan core protein, kininogen 1, v-clusters domain-containing inhibitor of T-cell activation 1, epidermal growth factor precursor, junctional adhesion molecule A, N-acetylated α-synaptide dipeptidase 2, transmembrane glycoprotein NMB, procollagen pro-c endopeptidase enhancer 2, urokinase plasminogen activator surface receptor, thrombospondin integrin metallopeptidase 1, cathepsin Z, cathepsin L1, endothelial cell selective adhesion molecule, kallikrein-1, complement component C9, complement component C1, calcium binding protein, complement component C7, aquaporin 2, follicle stimulating hormone beta subunit, protocadherin alpha-C2, vascular endothelial growth factor receptor 2, calcium adhesion-related family member 5, immunoglobulin heavy chain constant region gamma 4, aspartic proteinase A, or a combination thereof;

[0032] 4) Compare the protein expression levels in samples obtained from controls.

[0033] In specific embodiments, expression levels are determined using mass spectrometry, ELISA, or Western methods.

[0034] When mass spectrometry is used to determine proteins and their expression levels, a protease digestion step may be included after the step of obtaining a urine sample. In a specific embodiment, the protein in the urine sample is fragmented using a protease.

[0035] According to some embodiments, there is provided a method for diagnosing hereditary angioedema in a subject, comprising the steps of:

[0036] 1) Obtain urine samples from subjects and controls,

[0037] 2) Determine the expression level of the following proteins in urine samples of the subjects and controls: plasma proteinase C1 inhibitor, hexokinases, phenazine biosynthesis domain protein, contractile protein alpha chain, profibrillin 1, cathepsin H precursor, IST1 homologue, malate dehydrogenase, Cochlin, disintegrating protein and metalloproteinase domain-containing protein 10, basement membrane-specific heparan sulfate proteoglycan core protein, kininogen 1, V-clusters domain-containing t-cell activation inhibitor 1, epidermal growth factor precursor, junctional adhesion molecule A, N-acetylated alpha-synuclein diphosphate peptidase 2, transmembrane glycoprotein NMB, procollagen c endopeptidase enhancer 2, urokinase plasminogen activator surface receptor, thrombospondin integrin metallopeptidase 1, cathepsin Z, cathepsin L1, endothelial cell selective adhesion molecule, kallikrein 1, complement component C9, complement component C1, calcium binding protein, complement component C7, aquaporin 2, follicle stimulating hormone beta subunit, protocadherin alpha-C2, vascular endothelial growth factor receptor 2, calcium adhesion-related family member 5, immunoglobulin heavy chain constant region gamma 4, aspartic proteinase A, or a combination thereof;

[0038] 3) comparing the expression level of the protein in the subject with the expression level of the protein in the control;

[0039] 4) Determining whether the subject suffers from hereditary angioedema, or assessing the risk of suffering from hereditary angioedema.

[0040] In a specific embodiment, an increased expression level of a protein selected from the following, compared to the protein level in the control, indicates that the subject has an increased risk of hereditary angioedema: contractile protein alpha chain, profibrillin 1, cathepsin H precursor, IST1 homolog, Cochlin, protein 10 containing disintegrating and metalloproteinase domains, basement membrane-specific heparan sulfate proteoglycan core protein, junctional adhesion molecule A, N-acetylated alpha-synaptide dipeptidase 2, transmembrane glycoprotein NMB, procollagen c endopeptidase enhancer 2, urokinase plasminogen activator surface receptor, thrombospondin integrin metallopeptidase 1, cathepsin Z, cathepsin L1, endothelial cell selective adhesion molecule, complement component C9, complement component C1, complement component C7, aquaporin 2, follicle-stimulating hormone beta subunit, protocadherin alpha-C2, vascular endothelial growth factor receptor 2, calcium adhesion-related family member 5, or a combination thereof.

[0041] In a specific embodiment, a decreased expression level of a protein selected from the following, as compared to the protein level in a control, indicates that the subject has an increased risk of developing hereditary angioedema: plasma proteinase C1 inhibitor, hexokinases, phenazine biosynthesis domain protein, malate dehydrogenase, kininogen 1, immunoglobulin heavy chain constant region gamma 4, V-domain containing T-cell activation inhibitor 1, epidermal growth factor precursor, kallikrein 1, aspartic proteinase A, calcium binding protein, or a combination thereof. BRIEF DESCRIPTION OF THE DRAWINGS

[0042] Figure 1 Shown is the ROC curve for the diagnosis of HAE when plasma proteinase C1 inhibitor, kallikrein 1, and thrombospondin integrin metallopeptidase 1 were used in combination. DETAILED DESCRIPTION

[0043] The present disclosure will be further illustrated by the following non-limiting examples. It is well known to those skilled in the art that many modifications may be made to the present disclosure without departing from the spirit of the present disclosure, and such modifications also fall within the scope of the present disclosure. Unless otherwise specified, the experimental materials used can be obtained from commercial companies.

[0044] Example 1. Collection and preparation of urine samples for mass spectrometry detection

[0045] Cohort 1: Morning urine samples of 28 patients with hereditary angioedema from Peking Union Medical College Hospital, Chinese Academy of Medical Sciences (19 females, 9 males; average age 42.6 years) were obtained; and the urine protein expression was compared with that of 29 healthy controls (20 females, 9 males; average age 43.0 years). Cohort 2: Morning urine samples of 24 patients with hereditary angioedema from Peking Union Medical College Hospital, Chinese Academy of Medical Sciences (15 females, 9 males; average age 42.8 years) were obtained; and the urine protein expression was compared with that of 18 healthy controls (15 females, 3 males; average age 41.8 years). This study was approved by the ethics committee, and the patients signed the informed consent.

[0046] Controls were healthy individuals without hereditary angioedema.

[0047] The steps for preparing urine samples for mass spectrometry are as follows:

[0048] 1) Collect urine from hereditary angioedema patients and controls;

[0049] 2) Extract urine protein from patients: centrifuge the patient's urine at 5000g for 30 minutes, take the supernatant, mix the urine with acetone at a volume ratio of 1:4, and precipitate urine protein at -20℃ overnight. Centrifuge at 12000g for 30 minutes at 4℃, discard the supernatant, air-dry the precipitate, and then re-dissolve it in lysis buffer;

[0050] 3) Proteome sample preparation: Urine protein was digested on membrane using FASP method, see Wisniewski JR et al. Universal sample preparation method for proteome analysis. Nature methods 2009; 6: 359-62.

[0051] Example 2. Urine protein spectrum analysis

[0052] 1. Materials and Reagents

[0053] 1) Instrument:

[0054] Orbitrap Q Exactive HF high-resolution mass spectrometer was purchased from Thermo Fisher; high performance liquid chromatography EASY-nLC 1200 was purchased from Thermo Fisher.

[0055] 2) Reagents:

[0056] Chromatographic grade acetonitrile, formic acid and methanol were produced by Waters; iodoacetyl ammonium (IAA), ammonium bicarbonate and dithiothreitol (DTT) were purchased from Sigma; and mass spectrometry grade trypsin was purchased from Promega.

[0057] 2. Mass spectrometry identification

[0058] The peptides digested in cohort 1 were analyzed by tandem mass spectrometry using an Orbitrap Q Exactive HF high-resolution mass spectrometer, and mass spectrometry data were collected using the DIA quantitative proteomics technique. Then, the selected target proteins in cohort 2 were verified using the PRM targeted proteomics quantitative technique. DIA parameter settings: modify the mass spectrometry variable window, scan time is 60 min, collision energy: 28%; primary scan resolution is set to 60,000, secondary resolution is 30,000; parent ion maximum injection time is 80 ms; parent ion scan range: 300-1300 m / z; daughter ion scan range: starting from 350 m / z; set 40 scan windows; window size is determined according to the number of primary parent ions and evenly distributed. PRM parameter settings: each full scan is followed by 25 targeted scans, and the scan time is 60 min. The primary full scan resolution was 60,000, the scan range was 300-1250 m / z, AGC 3e6, the maximum injection time was 80 ms; the collision energy was 28%, and the secondary scan resolution was 30,000.

[0059] 3. Proteomic Quantitative Analysis

[0060] The obtained DIA mass spectrometry data was retrieved by Proteome Discoverer software (version 2.1), and the result file was imported into Spectronaut software to establish a spectrum library. The raw mass spectrometry data of the DIA formal sample was imported into Spectronaut software and matched with the data in the spectrum library. The q value was <1.0%, and the retention time was corrected by iRT reagent. Proteins with more than two specific peptides were screened and identified for subsequent proteome quantification. Proteins with a protein expression change of more than 1.5 times and a p value of less than 0.05 were screened as differential proteins. In PRM targeted quantification, 6-pin DDA data were first collected with a mixed sample and searched using Proteome Discoverer software. The search results were imported into Skyline software to establish a spectrum library. The protein sequence Fasta file of targeted quantification was imported into the Skyline spectrum library, and the m / z and retention time table of the corresponding peptides of the targeted protein were exported. The collected PRM raw data was imported back to Skyline, the quantitative fragment ions were screened, and the secondary fragment ion peak area of ​​each peptide was exported for PRM quantification.

[0061] 4. Mass spectrometry analysis results

[0062] In cohort 1, urine samples from 28 confirmed hereditary angioedema patients and 29 healthy controls were collected. A total of 1,897 proteins were identified, with at least two specific peptides and protein identification FDR < 1%.

[0063] By comparing with the control samples, differentially expressed proteins with a change fold of more than 1.5 and an independent sample t-test p < 0.05 were screened out, and 35 differentially expressed proteins could be used as diagnostic markers.

[0064] Table 1 shows that there are 35 candidate markers in total, 24 proteins were increased and 11 proteins were decreased compared with the control group.

[0065] Table 1. Differential urinary protein markers between hereditary angioedema patients and controls

[0066]

[0067]

[0068] Example 3. Application of urine protein markers in HAE diagnosis

[0069] To further confirm the sensitivity and specificity of the screened protein markers in the diagnosis of HAE, we used PRM targeted proteomics technology to validate the candidate markers in a new clinical cohort for the proteins in Table 1, and drew the ROC curves of the above markers in distinguishing HAE patients and subjects. The specific steps are as follows: In cohort 2, urine samples of 24 HAE patients (15 females and 9 males; average age 42.8 years) and 18 healthy control subjects (15 females and 3 males; average age 41.8 years) were newly collected. The expression levels of 7 differentially expressed proteins in the samples were tested by PRM targeted proteomics quantitative technology in a blinded manner, including plasma proteinase C1 inhibitor, profibrillin 1, epidermal growth factor precursor, malate dehydrogenase, kininogen 1, kallikrein 1, and thrombospondin integrin metallopeptidase 1. The results showed that compared with healthy controls, the fold change of plasma proteinase C1 inhibitor in patients' urine was 0.32, the fold change of profibrillin 1 was 1.48, the fold change of epidermal growth factor precursor was 0.50, the fold change of malate dehydrogenase was 0.49, the fold change of kallikrein 1 was 0.50, the fold change of thrombospondin integrin metallopeptidase 1 was 2.10, and the fold change of aspartic proteinase A was 0.46. The expression levels of these proteins (alone or in combination) can distinguish HAE patients and subjects.

[0070] For example, Figure 1 As shown in Figure 2, the combination of plasma proteinase C1 inhibitor, kallikrein 1, and thrombospondin integrin metallopeptidase 1 has a good diagnostic effect on HAE, with an area under the ROC curve (AUC) value of 0.925 ( Figure 1 ).

Claims

1. Use of an identification reagent in the preparation of a device for diagnosing hereditary angioedema in a subject, wherein the identification reagent specifically identifies a combination of the following proteins in urine: A combination of plasminogen activator protein C1 inhibitor, kallikrein 1, and thrombospondin integrin metallopeptidase 1. The device is a kit or a chip.

2. The use according to claim 1, wherein The subject is a mammalian subject.

3. The use according to claim 1, wherein The subject is a human.

4. The use according to any one of claims 1 to 3, wherein the identification reagent is selected from: a mass spectrometry identification reagent, an antibody or an antigen-binding fragment thereof.

5. The use according to claim 4, wherein the antibody is a monoclonal antibody.

6. The use according to claim 4, wherein the mass spectrometry identification reagent comprises a mass spectrometry identification parameter.

7. The use according to any one of claims 1 to 3, wherein: Decreased expression levels of plasma proteinase C1 inhibitor and kallikrein 1, and increased expression levels of thrombospondin integrin metallopeptidase 1, relative to a control, indicate that the subject has hereditary angioedema or is at increased risk of developing hereditary angioedema.